Phacilitate Leaders Forum

Speakers

Loading
Sybil Danby

Sybil Danby

Director Business Development, Paragon Bioservices

Sybil Danby, M.S., Director of Business Development joined Paragon in 2016 with 11 years of industry experience across both technical and commercial roles. Prior to joining Paragon Sybil was part of the Single Use Technologies Business Unit at Pall, supporting upstream customers to adopt innovative single-use bioreactor technologies for the production of recombinant proteins, virus-mediated therapies, and whole cell products. Sybil spent 9 years at GSK in both Commercial Manufacturing and Process Development, supporting the development, technology transfer, and manufacture of multiple clinical and commercial monoclonal antibody products. During her time at GSK Sybil developed extensive expertise in the area of bioreactor scaling and cell culture process development, with hands on experience developing and characterizing an upstream process from the bench to 5000L scale for an FDA approved product. Sybil obtained her B.A. in Biology from the University of Rochester and her M.S. in Biology from West Chester University of Pennsylvania.

Sessions
Testimonials
  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Jean-Philippe Combal
    GenSight Biologics
  • The conference consistently proves to be a great forum for networking with industry leaders in the development of cellular and gene therapies as well as vendors for important technologies and services.
    Michael Covington
    Juno Therapeutics, Inc
  • It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance
    Bertrand Alexandre
    Celyad
  • Phacilitate EU delivered it's promise and more, the topics discussed were highly relevant, with very good and professional speakers and panelists. You will see me next year in Berlin.
    Dr Ohad Karnieli
    Karnieli Ltd